Journal of Alzheimers Disease & Parkinsonism
Open Access

Biography

Dr. Cara Westmark is an Associate Scientist at the Waisman Center for Developmental Disabilities at the University of Wisconsin-Madison. Her current research examines the role of genetic and environmental factors on the expression of amyloid precursor protein (APP) and beta-amyloid (A beta) in transgenic mouse models of neurological disorders. She has demonstrated that APP/ A beta levels are altered in Fragile X syndrome and that many FXS phenotypes can be rescued in a mouse model of the disorder by genetically reducing APP/ A beta. These data suggest that therapies studied for the treatment of Alzheimer’s disease (AD) may be beneficial in the treatment of FXS. She has also demonstrated a strong association between APP/ A beta over-expression and lower seizure threshold, which has important implications for the treatment of seizure-related disorders such as AD, FXS and Down syndrome. Her most recent work has demonstrated a strong association between dietary phytoestrogen consumption, elevated A beta and reduced seizure threshold.

Research Interest

Cara current research examines the role of genetic and environmental factors on the expression of amyloid precursor protein (APP) and beta-amyloid (A Beta) in transgenic mouse models of neurological disorders.

Certificate

Global Speakers in the subject

Global Experts in the subject

Publications

Effect of Anticoagulants on Amyloid^®-Protein Precursor and Amyloid Beta Levels in Plasma

Cara J. Westmark, Crystal M. Hervey, Elizabeth M. Berry-Kravisc and James S. Maltera

Rapid Communication: J Alzheimers Dis 2011, 1:101

DOI: 10.4172/2161-0460.1000101